AMRI Appoints Director of Global Project Management
Share:
ALBANY, N.Y. -- AMRI (NASDAQ: AMRI) has named Michael D. Ironside, Ph.D. as director of global project management reporting to Dr. Steven Hagen, vice president of pharmaceutical development and manufacturing.
In this newly created role, Dr. Ironside will be responsible for overseeing all project management activities related to products moving through AMRI's pharmaceutical services organization.
Dr. Ironside brings over 18 years of experience in the pharmaceutical industry. Most recently, he served in a consultant role as president of Rondaxe Scientific Solutions. Before joining Rondaxe, he was chief scientific officer at Biosignal, an emerging biotech company in Australia. Dr. Ironside also brings over 8 years of significant prior relevant AMRI experience, joining the company in 1998 as a section head in chemical development and subsequently assuming increased levels of responsibility culminating in the oversight and leadership of AMRI's chemical development and small scale cGMP (current Good Manufacturing Practice) unit.
Dr. Ironside holds a Ph.D. in organic chemistry from Dundee University in Scotland and was a postdoctoral fellow at Sydney University in Australia.
AMRI Vice President, Pharmaceutical Development and Manufacturing Steven Hagen said, "Dr. Ironside's significant experience in project management and customer relations activities, in addition to his hands-on knowledge of the AMRI organization, make him an immediately value-added member of our organization. As we continue to grow in the area of manufacturing services, the ability to seamlessly manage projects across the pharmaceutical development spectrum adds value to our customers through enhancement of knowledge transfer, elevated level of quality and shorter time to deliver."
About AMRI
Founded in 1991, Albany Molecular Research, Inc. (AMRI) provides scientific services, products and technologies focused on improving the quality of life. AMRI works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for many of the world's leading healthcare companies. As an additional value added service to its customers, the company is also investing in R&D in order to expand its contract services and to identify novel early stage drug candidates with the goal to outlicense to a strategic partner. With locations in the U.S., Europe, and Asia, AMRI provides customers with a wide range of services, technologies and cost models.
Contacts
Media
AMRI Corporate Communications
Andrea Schulz, 518-512-2226
or
Investors
Peter Jerome, 518-512-2220
AMRI Director of Investor Relations
